ERBB2 and breast cancer: Notably, a truncated 95–100 kDa receptor (p95HER2), expressed in a minor portion of HER2-positive breast cancer patients, leads to an aggressive trastuzumab-resistant phenotype due to its lack of the extracellular domain of HER2 targeted by trastuzumab [16].